Blogs

MSD's record-breaking $10 billion acquisition of Verona Pharma illustrates the potential of our sector, but also is a reminder of the need to strengthen UK capital markets.

In this blog, James Buckley-Walker, Partner, 3PM, shares his vision of a smarter, more human-focused approach to lab design and operation.

In this article, Kate Barclay, Skills Strategy Consultant at BIA, outlines new changes to UK immigration law and how they will impact the life sciences sector. Prepared in collaboration with legal experts at Eversheds-Sutherland LLP.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.

NHS 10 Year Health Plan for England, a strategy for European Life Sciences and hope to see you at the “sunny” BIA Summer Party on Wednesday.

In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.

OK, I admit defeat. The UK government has published 3.5 key strategies that affect our sector in a week and I’m expecting at least two more in the coming days – a full analysis of so much text by today is beyond me but…

In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.

The Data (Use and Access) Act became law last week – but what does it mean for the life science sector? Fredericka Argent, Paul Maynard, and Tom Griffiths from Covington and Burling’s technology regulatory team explain all in this blog.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

In this Q&A blog, BIA spoke to Natasha Gray, Associate & Life Sciences Advisory Service Lead at Warn, a new BIA member.

UK life sciences take centre stage at BIO following a promising Spending Review.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares his insights on BIA's recent Start-up Festival.

An experienced clinician scientist and surgery consultant, Dr Gianmarco Contino brings deep expertise in gastrointestinal cancers and cancer genomics.

Positive news ahead of Spending Review (join our webinar this Friday), latest on getting pensions investment into UK life sciences and more!

In this blog, Kate Barclay, Skills Consultant at BIA, introduces Skills England, a new Executive Agency within the Department for Education.

At BIA’s recent Start-up festival, we caught up with Mark Bartlett, CEO of StoreGene, to learn more about his journey, what drives him, and his advice for founders navigating the world of genomics and startups.

In this blog Richard Turner, the new vice chair of FTAC, examines the UK's overhauled R&D tax regime, which provides competitive incentives and a stable fiscal framework.

Pension capital is unlocked in time for BIA's Parliament Day this Wednesday.